The Pharma Data

DECEMBER 29, 2020

30, 2020 11:00 UTC. Insights from Optimity app user survey finds that 43% believe the COVID-19 vaccine should be mandatory, while 53% believe that Canadians should have a choice of which vaccine to receive. The primary reason cited for selecting a particular manufacturer was that Canada had approved the vaccine (24%).

Vaccine 52

Vaccine Science Government Research 52

Drug Discovery World

APRIL 17, 2023

“Over 90% of HPV-associated cancers could be prevented with the HPV vaccination, yet vaccine uptake remains suboptimal,” explained the study’s lead author, Eric Adjei Boakye, Assistant Scientist in the Department of Health Sciences and the Department of Otolaryngology at Henry Ford Health in Detroit. Currently, about 54.5%

Vaccine 130

Vaccine FDA Approval FDA Science 130

The Pharma Data

MAY 6, 2021

Under the MoU, the companies and the IOC will coordinate with National Olympic Committees (NOCs) around the world to understand and work to help address the local need for vaccine doses for national delegations’ participation in the Games. This press release features multimedia. View the full release here: [link].

Vaccine 52

Vaccine Clinical Trials Licensing Licensing 52

Eye on FDA

JANUARY 6, 2021

During 2020, FDA was able to approve 53 – not surpassing the 2018 all time record of 59, but certainly an admirable second place. Notably, the 2020 NME approvals included 22 related to oncology, with 2 new GIST treatments, 3 in breast cancer and 2 approvals in prostate cancer. That, however, was not really the case.

FDA 82

FDA Vaccine Clinical Trials Treatment 82

The Pharma Data

DECEMBER 17, 2020

COVID-19 vaccine developers are faced with an ethical quandary — whether to let phase 3 trial participants become “unblinded” and to receive authorized vaccines as they become available, which could hinder the collection of meaningful trial data. Pfizer, which has received emergency approvals in the U.S.

Vaccine 52

Vaccine Trials Long-Term Care Facilities FDA 52

The Pharma Data

NOVEMBER 10, 2020

Russia’s Gamaleya Center Research Institute claimed its investigational COVID-19 vaccine, Sputnik V, has demonstrated 92 percent efficacy in a late-stage trial. The finding was based on interim data from a phase 3 study, based on 20 confirmed cases of COVID-19, split across patients given the vaccine and patients given the placebo.

Vaccine 52

Vaccine Government Trials Research 52

The Pharma Data

NOVEMBER 9, 2020

Pfizer announced that its COVID-19 vaccine candidate, BNT162, was more than 90 percent effective based on early data from 94 participants in a phase 3 trial. Pfizer, which is developing the vaccine along with Germany-based BioNTech, expects to manufacture up to 50 million doses of the vaccine in 2020 and up to 1.3

Vaccine 40

Vaccine FDA Trials Research 40

The Pharma Data

DECEMBER 16, 2020

Moderna has revealed that it was impacted by last week’s cyberattack on the European Medicines Agency (EMA), during which hackers compromised agency computer systems and accessed vaccine regulatory submission documents for Pfizer/BioNTech’s and Moderna’s COVID-19 vaccines. biotech firms ( DID , July 22 ). James Miessler.

Vaccine 52

Vaccine Regulations Government FDA 52

The Pharma Data

OCTOBER 25, 2020

German drugmaker CureVac said preclinical studies of its COVID-19 vaccine candidate, CVnCoV, showed the vaccination prompted a successful immune response. The messenger RNA-based vaccine, which is designed to block replication of the coronavirus, was shown to induce neutralizing antibodies and activate T-cells in hamsters and mice.

Vaccine 52

Vaccine Immune Response RNA Clinical Trials 52

The Pharma Data

DECEMBER 3, 2020

3, 2020 — All Americans who get a COVID-19 vaccine will get a vaccination card, officials say. associate director of the Immunization Action Coalition, which supports frontline workers who will administer COVID-19 vaccinations, CNN reported. © 2020 HealthDay. Posted: December 2020. THURSDAY, Dec.

Vaccine 52

Vaccine Disease 52

The Pharma Data

DECEMBER 28, 2020

EU Kicks Off COVID-19 Vaccine Campaign. Starting with health care workers and the elderly, the European Union has begun a massive program to vaccinate millions against COVID-19, according to the Associated Press. Austrian Chancellor Sebastian Kurz called the vaccine a “game-changer.” © 2020 HealthDay.

Vaccine 52

Vaccine Virus Nurses Science 52

The Pharma Data

DECEMBER 30, 2020

Becomes First Country to Approve Covid-19 Vaccine From Oxford-AstraZeneca. Britain became the first country to give authorization to the coronavirus vaccine developed by AstraZeneca and the University of Oxford, The New York Times reported Wednesday. © 2020 HealthDay. Posted: December 2020. All rights reserved.

Vaccine 52

Vaccine Pharmacy Packaging Production 52

The Pharma Data

DECEMBER 21, 2020

military scientists to determine if it might be resistant to vaccines. The deal also includes more than $30 billion to acquire and distribute coronavirus vaccines and $27 billion for testing and state health care programs. Higher flu vaccination rates are one reason why flu cases are way down in the United States, experts say.

Packaging 52

Packaging Vaccine Laboratories Virus 52

The Pharma Data

DECEMBER 14, 2020

Supported by promising phase 1 data, CureVac announced Monday that it has enrolled the first participant in the pivotal phase 2b/3 study of its messenger-RNA based coronavirus vaccine, CVnCoV. Like Pfizer and Moderna’s highly effective vaccines, CVnCoV is a two-dose vaccine based on mRNA technology. James Miessler.

Vaccine 52

Vaccine Trials Immune Response RNA 52

The Pharma Data

DECEMBER 22, 2020

The Pfizer COVID-19 vaccine was approved by the European Union (EU) on Monday and should soon be available in all 27 member nations. Deliveries of the vaccine are expected to begin this weekend, with shots beginning across the EU between Dec. © 2020 HealthDay. Posted: December 2020. 27 and Dec. All rights reserved.

Hospitals 52

Hospitals Vaccine 52

The Pharma Data

DECEMBER 11, 2020

The Australian government has scrapped a supply deal with CSL for 51 million doses of its COVID-19 vaccine co-developed with the University of Queensland, after trial participants falsely tested positive for HIV.

Vaccine 52

Vaccine Immune Response Government Trials 52

The Pharma Data

NOVEMBER 13, 2020

We must collectively work to support countries and engage communities to reach everyone, everywhere with measles vaccine and stop this deadly virus.” This means ensuring we have the resources to continue immunization campaigns for all vaccine-preventable diseases, even as we address the growing COVID-19 pandemic.”

Vaccine 52

Vaccine Virus Disease Research 52

The Pharma Data

DECEMBER 7, 2020

China’s Clover Biopharmaceuticals has announced its COVID-19 S Trimer vaccine candidate delivered a “strong immune response” in 150 adult and elderly phase 1 trial participants, with pre-publication results to be released soon. based Dynavax Technologies to boost the vaccine’s efficacy. Jason Scott. Source link.

Vaccine 52

Vaccine Immune Response Clinical Trials Trials 52

The Pharma Data

DECEMBER 20, 2020

UK drug developer Scancell said it has chosen a COVID-19 vaccine candidate, SN14, from more than a dozen potential products to advance to a clinical trial. . SN14 works by targeting the coronavirus’ nucleocapsid and spike proteins to prevent viral replication using the company’s ImmunoBody DNA vaccine technology. Source link.

Clinical Trials 52

Clinical Trials Pharma Companies Vaccine Trials 52

The Pharma Data

DECEMBER 9, 2020

Canada Approves Pfizer COVID-19 Vaccine. 9, 2020 — The Pfizer COVID-19 vaccine has been approved by Canada’s health agency and the first Canadians could start receiving it next week. Britain approved the vaccine earlier, but it was an emergency approval largely based on the Pfizer analysis. © 2020 HealthDay.

Vaccine 52

Vaccine 52

The Pharma Data

NOVEMBER 23, 2020

Third COVID-19 Vaccine Shows Effectiveness. 23, 2020 — On Monday, AstraZeneca announced that late-stage clinical trials of its COVID-19 vaccine showed it to be 70.4 The AstraZeneca vaccine becomes the third vaccine to show good effectiveness, following on the heels of promising data on vaccines from Pfizer and Moderna.

Vaccine 52

Vaccine Clinical Trials Virus Trials 52

The Pharma Data

NOVEMBER 18, 2020

19, 2020 /PRNewswire/ — OBI Pharma, Inc. These results will be presented by the lead investigators of OBI Pharma’s novel anti-Globo H therapeutic cancer vaccine, OBI-833. Session Date and Time: Friday, November 20, 2020. Session Date and Time: Friday, November 20, 2020. TAIPEI, Taiwan , Nov. About OBI Pharma.

Vaccine 52

Vaccine Small Molecule Immune Response Hospitals 52

The Pharma Data

NOVEMBER 11, 2020

Moderna has released promising early results from a small phase 1 trial of its experimental personalized cancer vaccine, mRNA-4157, in combination with Merck’s Keytruda (pembrolizumab). The study enrolled 10 patients with human papillomavirus- (HPV) negative head and neck cancer and 17 colorectal cancer patients. drugmaker said.

Vaccine 52

Vaccine Trials Research 52

The Pharma Data

NOVEMBER 18, 2020

Both Moderna’s and Pfizer’s COVID-19 vaccine candidates could receive Emergency Use Authorization (EUA) in less than a month and be ready for rollout in a matter of weeks, HHS Secretary Alex Azar said Wednesday, giving hope that high-risk patients could receive a vaccine before the year ends.

Vaccine 52

Vaccine Government Immune Response FDA 52

The Pharma Data

OCTOBER 22, 2020

Moderna has completed enrollment of 30,000 participants for its phase 3 study evaluating COVID-19 vaccine candidate mRNA-1273. Moderna CEO Stéphane Bancel said the company’s COVID-19 vaccine won’t be available for widespread distribution until Spring 2021, most likely late in the first quarter or early in the second quarter.

Vaccine 52

Vaccine Trials Disease Research 52

PPD

MAY 11, 2023

The global COVID-19 pandemic increased awareness of the importance of vaccine development — both for drug developers and the public. The speed at which COVID-19 vaccines were developed was remarkable, but like most newly developed vaccines, there was variation among who could receive the shots and when.

Vaccine 52

Vaccine Clinical Trials Long-Term Care Facilities Trials 52

The Pharma Data

DECEMBER 11, 2020

Marshals to Protect COVID-19 Vaccines. 11, 2020 — COVID-19 vaccines will be protected by U.S. Food and Drug Administration is expected to quickly give emergency authorization to the Pfizer COVID-19 vaccine, which would be followed by an undertaking to distribute 3 million doses of the vaccine nationwide, CBS News reported.

Vaccine 52

Vaccine Drugs 52

The Pharma Data

NOVEMBER 12, 2020

German drugmaker Curevac says its COVID-19 vaccine candidate, CVnCoV, can remain stable for at least three months at 41 degrees Fahrenheit (5 degrees Celsius), making it easier to distribute than some competitors’ vaccines. The company hopes to launch a phase 3 trial by year’s end. Source link.

Vaccine 52

Vaccine Trials Research 52

The Pharma Data

JANUARY 21, 2021

Percent of Kindergarteners Not Up to Date With MMR in 2019-2020. percent of kindergarteners were not up to date with measles, mumps, and rubella (MMR) vaccination and did not have an exemption in the 2019 to 2020 school year, according to research published in the Jan. The researchers found that vaccination coverage was 94.9,

Vaccine 52

Vaccine Disease Research 52

The Pharma Data

DECEMBER 18, 2020

Indigenous Communities Start Receiving COVID-19 Vaccines. 18, 2020 — Indigenous communities in the United States have started receiving COVID-19 vaccines from federal and state agencies. Other tribes will receive vaccine deliveries through state health agencies, the AP reported. © 2020 HealthDay. .

Vaccine 52

Vaccine Government 52

The Pharma Data

DECEMBER 8, 2020

AstraZeneca (AZ) and the University of Oxford have presented new data from a “pooled analysis” of phase 3 trials evaluating COVID-19 vaccine AZD1222 at two different dose regimens, demonstrating an average efficacy of 70.4 The University of Oxford claims no vaccinated participants were hospitalized or suffered serious forms of the disease.

Vaccine 52

Vaccine Trials Hospitals Disease 52

Eye on FDA

MARCH 5, 2023

Note these numbers cover meetings about drug applications only, not including vaccines or cellular therapies. That said, beginning in 2020 meetings began skewing to more negative outcomes and 2022 was the first year where the number of negative outcomes outweighed the number of positive outcomes.

FDA 72

FDA Vaccine Drugs Therapies 72

The Pharma Data

OCTOBER 18, 2020

UK-based contract research organization Open Orphan said it is in advanced negotiations with the British government and other partners for a human challenge trial of a COVID-19 vaccine. Any challenge trial must first be cleared by the Medicines and Healthcare products Regulatory Agency, which oversees the safety of medicines in the UK.

Vaccine 52

Vaccine Trials Government Production 52

The Pharma Data

OCTOBER 15, 2020

UK-based contract research organization Open Orphan said it is in advanced negotiations with the British government and other partners for a human challenge trial of a COVID-19 vaccine. Any challenge trial must first be cleared by the Medicines and Healthcare products Regulatory Agency, which oversees the safety of medicines in the UK.

Vaccine 52

Vaccine Trials Government Production 52

The Pharma Data

NOVEMBER 3, 2020

The Coalition for Epidemic Preparedness Innovations (CEPI) has agreed to fund development of a potential COVID-19 vaccine from China’s Clover Biopharmaceuticals with a global phase 2/3 study and through licensing and distribution. million investment announced in July. Earlier this year, CEPI provided $3.5

Vaccine 52

Vaccine Trials Licensing Licensing 52

The Pharma Data

DECEMBER 7, 2020

China’s Clover Biopharmaceuticals has announced its COVID-19 S Trimer vaccine candidate delivered a “strong immune response” in 150 adult and elderly phase 1 trial participants, with pre-publication results to be released soon.

Vaccine 52

Vaccine Immune Response Trials Research 52

The Pharma Data

DECEMBER 7, 2020

Inovio has dosed the first participant in the phase 2 segment of its phase 2/3 trial evaluating COVID-19 vaccine candidate INO-4800, funded by the Department of Defense (DoD). sites to assess the vaccine’s safety, tolerability and immunogenicity as a two-dose regimen. The Plymouth Meeting, Pa., The Plymouth Meeting, Pa.,

Vaccine 52

Vaccine Trials Research 52